RET protein inhibitor（Eli Lilly and Company）

N/A

Report date: 2023/02/21 14:04:44
NME

Base Information

Drug NameRET protein inhibitor（Eli Lilly and Company）
Drug Alias NameRET Inhibitor II
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A